Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis

Jana Volejnikova,[1] Ester Mejstrikova,[1] Tatana Valova,[1] Leona Reznickova,[1] Ladislava Hodonska,[1] Vladimir Mihal,[2] Jaroslav Sterba,[3] Yahia Jabali,[4] Daniela Prochazkova,[5] Bohumir Blazek,[6] Jiri Hak,[7] Zdenka Cerna,[8] Ondrej Hrusak,[1] Jan Stary,[1] Jan Trka,[1] and Eva Fronkova[1]

[1]Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague; CLIP - Childhood Leukemia Investigation Prague; [2]Department of Pediatrics, Palacky University and University Hospital Olomouc; [3]Department of Pediatric Oncology, Masaryk University and University Hospital Brno; [4]Department of Pediatrics, Regional Hospital Ceske Budejovice; [5]Department of Pediatrics, Masaryk Hospital Usti nad Labem; [6]Department of Pediatrics, University Hospital Ostrava; [7]Department of Pediatrics, University Hospital Hradec Kralove, and [8]Department of Pediatrics, University Hospital Plzen, Czech Republic

Citation: Volejnikova J, Mejstrikova E, Valova T, Reznickova L, Hodonska L, Mihal V, Sterba J, Jabali Y, Prochazkova D, Blazek B, Hak J, Cerna Z, Hrusak O, Stary J, Trka J, and Fronkova E. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica 2011;96(12):1815-1821. doi:10.3324/haematol.2011.042937

Online Supplementary Table S1. Representativeness of the study cohort.

		Total cohort (n=166)		Study cohort (n=95)		p
Immunophenotype						
	cALL	**118**	71 %	**67**	71 %	
	PreB	**42**	25 %	**24**	25 %	p=0.97
	ProB	**6**	4 %	**4**	4 %	
Genetics						
	TEL/AML1	**54**	33 %	**31**	33 %	
	Hyperdiploid	**45**	27 %	**28**	29 %	p=0.90
	Other	**67**	40 %	**36**	38 %	
Age						
	<6 years	**104**	63 %	**62**	65 %	
	>6 years	**62**	37 %	**33**	35 %	p=0.67
White blood cell count						
	<20,000	**117**	70 %	**71**	75 %	
	>20,000	**49**	30 %	**24**	25 %	p=0.46
Gender						
	Male	**86**	52 %	**48**	51 %	
	Female	**80**	48 %	**47**	49 %	p=0.84
ALL- IC risk group						
	SR	**69**	42 %	**45**	47 %	
	IR	**86**	52 %	**46**	48 %	p=0.54
	HR	**11**	7 %	**4**	4 %	
BM morphology at day 15						
	M1	**110**	66 %	67	71 %	
	M2	**41**	25 %	24	25 %	p=0.35
	M3	**15**	9 %	4	4 %	
Ikaros alteration						
	Yes	**11**	8 %	**6**	7 %	
	No	**126**	92 %	**77**	93 %	p=0.83
Relapse						
	No	**147**	89 %	**81**	85 %	
	Yes	**19**	11 %	**14**	15 %	p=0.44

SR: standard risk; IR: intermediate risk; HR: high risk.

Online Supplementary Table S2. Representativeness of the cohort with information available on minimal residual disease on day 15.

		Total cohort (n=166)		Day 15 cohort (n=78)		p
Immunophenotype						
	cALL	**118**	71 %	**58**	74 %	
	PreB	**42**	25 %	**18**	23 %	p=0.83
	ProB	**6**	4 %	**2**	3 %	
Genetics						
	TEL/AML1	**54**	33 %	**28**	36 %	
	Hyperdiploid	**45**	27 %	**21**	27 %	p=0.85
	Other	**67**	40 %	**29**	37 %	
Age						
	<6 years	**104**	63 %	**50**	64 %	
	>6 years	**62**	37 %	**28**	36 %	p=0.83
WBC						
	<20,000	**117**	70 %	**61**	78 %	
	>20,000	**49**	30 %	**17**	22 %	p=0.21
Gender						
	Male	**86**	52 %	**39**	50 %	
	Female	**80**	48 %	**39**	50 %	p=0.79
ALL- IC risk group						
	SR	**69**	42 %	**36**	46 %	
	IR	**86**	52 %	**39**	50 %	p=0.60
	HR	**11**	7 %	**3**	4 %	
BM morphology at day 15						
	M1	**110**	66 %	**54**	69 %	
	M2	**41**	25 %	**21**	27 %	p=0.35
	M3	**15**	9 %	**3**	4 %	
Ikaros alteration						
	Yes	**11**	8 %	**5**	6 %	
	No	**126**	92 %	**73**	94 %	p=0.66
Relapse						
	No	**147**	89 %	**65**	83 %	
	Yes	**19**	11 %	**13**	17 %	p=0.26

SR: standard risk; IR: intermediate risk; HR: high risk



Online Supplementary Figure S1. Relationship between minimal residual disease (MRD) in bone marrow and the occurrence of relapse. Quantitative MRD levels (logarithmic scale) in bone marrow at days 8, 15, and 33. n.s.: non-significant.